Estimated annual spending on Lecanemab and its ancillary costs in the Medicare program

(Press-News.org) About The Study: Lecanemab and associated ancillary services could add an estimated $2 billion to $5 billion annually to Medicare spending with substantial out-of-pocket costs for beneficiaries lacking supplemental coverage, according to a cost analysis using nationally representative survey data. Lecanemab, an antidementia medication with modest clinical benefit, received accelerated Food and Drug Administration approval. 

Authors: John N. Mafi, M.D., M.P.H., of the David Geffen School of Medicine at the University of California, Los Angeles, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2023.1749)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The study is being released to coincide with presentation at the 2023 Society of General Internal Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2023.1749?guestAccessKey=858dd927-1a6d-4299-a6a8-9d6998732430&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051123

END